ArticleJournal of analytical methods in chemistry2026
Harnessing the Structural Variability of Doxycycline Hyclate: Mechanistic Insights and Comparative Assessment of Four Chemically Diverse Spectrophotometric Pathways.
Article in Journal of analytical methods in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing the Structural Variability of Doxycycline Hyclate: Mechanistic Insights and Comparative Assessment of Four Chemically Diverse Spectrophotometric Pathways.Journal of analytical methods in chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Four distinct, chemically asynchronous spectrophotometric pathways each tapping into a different reactive node of the polyfunctional doxycycline hyclate (DOX) framework were planned to bypass the limitations of single mechanism assays. It works amazingly well. By exploiting the drug's inherent structural mutability, we developed a multipronged quantification matrix. Take the drug's reducing capacity, for instance. In Method A, this specific driving force reduces Fe (III) in the presence of potassium ferricyanide, yielding a highly conjugated Turnbull's blue complex characterized by a distinct bathochromic shift (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.